

**I. Amendments to the Claims Pursuant to 37 C.F.R. § 1.121 (c)**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously amended.) A pharmaceutical and/or cosmetic product comprising first and second active ingredient-containing formulations for topical administration to the skin, hair or nails of a mammal, wherein said product includes storage means whereby said formulations are maintained separately prior to dispense, together with dispense means which permit said formulations to be dispensed from said storage means, characterised in that (i) an active ingredient in at least one of said formulations is contained within a polymeric delivery system and (ii) both of said formulations comprise water-based carrier bases having substantially the same lipophilicity.
2. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein said formulations each comprise aqueous carrier bases.
3. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 2 wherein the polymeric delivery system is comprised of a plurality of crosslinked porous polymer particles forming a porous polymeric matrix in which is contained an active ingredient.
4. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the dispense means are such as to permit dispense of the first formulation in a specific ratio to the second formulation.

5. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the storage means comprise side-by-side chambers each equipped with a dispense valve, said valves being operable by adjacently disposed actuators.

6. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the storage means comprise a unit dose pouch having separate parts for each formulation.

7. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the dispense means are adapted to dispense said formulations separately.

8. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first formulation is an aqueous topical cream or gel carrier base containing an antibacterial and/or keratolytic agent incorporated into a polymeric delivery system and the second formulation is an aqueous carrier base having substantially the same lipophilicity as the first formulation and containing a topical antibiotic.

9. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein said keratolytic agent is a retinoid.

10. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 9 wherein the retinoid is selected from the group consisting of retinoic acid, tazarotene and adapalene.

11. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein the antibacterial agent is salicylic acid or an organic peroxide.

12. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 11 wherein said organic peroxide is benzoyl peroxide.

13. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein the antibacterial and/or keratolytic agent incorporated into a polymeric delivery system is selected from the group consisting of retinoids, salicylic acid and organic peroxides and ~~said~~ the antibiotic is selected from the group consisting of erythromycin, clindamycin or a tetracycline.

14. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 13 wherein the antibacterial and/or keratolytic agent is benzoyl peroxide and the topical antibiotic is clindamycin.

15. (Canceled).

16. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients an anti-fungal agent and a retinoid, at least one of which is incorporated into a polymeric delivery system.

17. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 16 wherein the anti-fungal agent is selected from the group consisting of undecilenic acid, miconazole, in the form of a base or nitrate, ketoconazole, iconazole, clotrimazole and the retinoid is either retinol or retinoic acid.

18. (Previously amended.) A pharmaceutical and/or cosmetic product according to according to claim 3 which comprises as active ingredients a depigmenting agent and a keratolytic agent, at least one of which is incorporated into a polymeric delivery system.

19. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a depigmenting agent and a retinoid, at least one of which is incorporated into a polymeric delivery system.

20. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 19 which further comprises a corticosteroid.

21. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a corticosteroid and a retinoid at least one of which is incorporated into a polymeric delivery system.

22. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a hair growth promoter and a retinoid or other keratolytic agent, at least one of which is incorporated into a polymeric delivery system.

23. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein said first and second formulations have substantially the same water content.

24. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein said first and second formulations have substantially the same viscosity.

25. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 comprising more than two active ingredient-containing formulations for topical administration to the skin, hair or nails of a mammal, together with storage means whereby each of said formulations is separately maintained prior to dispense, wherein (i) an active ingredient in at least one of said formulations is contained within a polymeric delivery system comprised of a plurality of crosslinked porous polymer particles forming a porous polymeric matrix in which is contained an active ingredient and (ii) all of said formulations comprise water-based carrier bases having substantially the same lipophilicity.

26. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises a dual or multi-chamber dispense system having an actuator which causes dispense of said formulations from one or more orifices and a closure which (i) prevents depression of the actuator or (ii) covers or seals the orifice(s) of the dispense system.

27. (Canceled.)

28. (Canceled.)

29. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 40,000 cps.

30. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 30,000 cps.

31. (New.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 20,000 cps.

32. (New.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 10,000 cps.

33. (New.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 10%.

34. (New.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 5%.

35. (New.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 2.5%.